Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7122290 + cibisatamab with obinutuzumab pretreatment in previously treated MSS metastatic colorectal adenocarcinoma
NL-OMON51905Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RG7827, cibisatamab and obinutuzumab in colorectal adenocarcinoma (2 arms), sponsored by Roche. Primary endpoints: Dose-limiting toxicities and Adverse events. Started Jul 2021; status: completed.
02
Drugs
RG7827cibisatamabobinutuzumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON51905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51905.